Gemini Therapeutics (GMTX) Competitors $62.55 +3.00 (+5.04%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsTrends GMTX vs. PCVX, CTLT, SRPT, QGEN, RVMD, ITCI, ROIV, ASND, LEGN, and ELANShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Vaxcyte (PCVX), Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Revolution Medicines (RVMD), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Vaxcyte Catalent Sarepta Therapeutics Qiagen Revolution Medicines Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Legend Biotech Elanco Animal Health Vaxcyte (NASDAQ:PCVX) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings. Is PCVX or GMTX more profitable? Vaxcyte's return on equity of -23.53% beat Gemini Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% Gemini Therapeutics N/A -38.78%-35.88% Which has more volatility and risk, PCVX or GMTX? Vaxcyte has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Does the media refer more to PCVX or GMTX? In the previous week, Vaxcyte had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 13 mentions for Vaxcyte and 1 mentions for Gemini Therapeutics. Vaxcyte's average media sentiment score of 0.90 beat Gemini Therapeutics' score of 0.00 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings & valuation, PCVX or GMTX? Gemini Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$4.60-18.69Gemini TherapeuticsN/AN/A-$71.87M-$1.00-62.55 Does the MarketBeat Community believe in PCVX or GMTX? Vaxcyte received 25 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 74.58% of users gave Vaxcyte an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes4474.58% Underperform Votes1525.42% Gemini TherapeuticsOutperform Votes1963.33% Underperform Votes1136.67% Do analysts recommend PCVX or GMTX? Vaxcyte presently has a consensus price target of $147.50, indicating a potential upside of 71.55%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals believe in PCVX or GMTX? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryVaxcyte beats Gemini Therapeutics on 12 of the 15 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.71B$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-62.555.5697.3414.18Price / SalesN/A348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book21.647.885.805.12Net Income-$71.87M$153.61M$119.07M$225.99M7 Day Performance3.10%-2.00%-1.83%-1.32%1 Month Performance23.71%-7.47%-3.64%0.60%1 Year Performance22.38%31.80%31.62%26.23% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$62.55+5.0%N/A+14.7%$2.71BN/A-62.5530PCVXVaxcyte3.2938 of 5 stars$85.98+0.0%$147.50+71.6%+67.2%$10.72BN/A0.00160CTLTCatalent3.0395 of 5 stars$59.00+0.2%$63.40+7.5%+47.8%$10.71B$4.38B-26.1116,900SRPTSarepta Therapeutics4.914 of 5 stars$109.71-1.0%$181.33+65.3%+33.5%$10.48B$1.24B88.691,314Analyst DowngradeGap UpQGENQiagen4.4347 of 5 stars$42.25+0.4%$50.88+20.4%+2.5%$9.64B$1.97B107.975,967Positive NewsRVMDRevolution Medicines2.7869 of 5 stars$57.07+1.1%$61.00+6.9%+162.6%$9.60B$11.58M0.00443ITCIIntra-Cellular Therapies4.4721 of 5 stars$85.29-0.4%$97.23+14.0%+46.2%$9.04B$464.37M-98.44560Positive NewsROIVRoivant Sciences3.2845 of 5 stars$11.65+1.4%$17.93+53.9%+30.6%$8.62B$124.79M2.03860ASNDAscendis Pharma A/S3.0066 of 5 stars$124.380.0%$191.77+54.2%+32.7%$7.54B$288.08M0.00640Analyst UpgradeLEGNLegend Biotech1.7671 of 5 stars$40.05-0.2%$81.46+103.4%-33.7%$7.30B$285.14M0.001,800Analyst RevisionELANElanco Animal Health4.1237 of 5 stars$13.44+1.0%$17.14+27.6%+13.1%$6.64B$4.42B33.609,300 Related Companies and Tools Related Companies Vaxcyte Alternatives Catalent Alternatives Sarepta Therapeutics Alternatives Qiagen Alternatives Revolution Medicines Alternatives Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GMTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
